Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn's disease

Clin Imaging. Sep-Oct 2011;35(5):360-5. doi: 10.1016/j.clinimag.2010.09.003.

Abstract

To evaluate a magnetic resonance imaging (MRI)-based score of disease severity for perianal fistulizing Crohn's disease (CD), 16 patients with perianal fistulizing CD underwent 1.5-T MRI before and after infliximab therapy. MRI scores, Perianal Disease Activity Index (PDAI) and C-reactive protein (CRP) were calculated, and fistula drainage was assessed. These items were compared for responders and nonresponders. After therapy, PDAI values and CRP values decreased significantly in responders, but there were no significant differences in the MRI scores. In all responders, MRI findings were indicative of persisting active inflammation. In these patients, a relapse rate of 57% was seen.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers / analysis
  • C-Reactive Protein / analysis
  • Crohn Disease / drug therapy
  • Crohn Disease / pathology*
  • Female
  • Gadolinium DTPA
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Rectal Fistula / pathology*
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Gastrointestinal Agents
  • gadodiamide
  • C-Reactive Protein
  • Infliximab
  • Gadolinium DTPA